|Bid||4.3000 x 3200|
|Ask||4.3600 x 1300|
|Day's Range||4.2500 - 4.5541|
|52 Week Range||1.3800 - 6.2900|
|Beta (5Y Monthly)||2.75|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.50|
Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX) are up 14.5% at 1:16 p.m. after the biotech's new CFO, Anthony Doyle, purchased 54,000 shares of the company at $4.08 per share. As they say, there are many reasons an executive might feel the need to sell shares, but there's only one reason to buy: Doyle clearly thinks shares are undervalued at this point. BioCryst's valuation has increased dramatically as investors have rushed in ahead of anticipated approvals in the U.S. and Japan for its hereditary angioedema treatment, Orladeyo.
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
BioCryst (BCRX) delivered earnings and revenue surprises of 14.29% and -9.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?